Does Mounjaro Reduce Inflammation? The Mechanism, Clinical Data, and What It Means for Chronic Disease Risk

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) reduces C-reactive protein (CRP) by 30-40% and interleukin-6 (IL-6) by 20-35% in clinical trials, independent of weight loss
• The anti-inflammatory effect appears within 4-8 weeks and persists through 72 weeks of treatment
• Inflammation reduction likely contributes to cardiovascular benefits beyond glucose and weight control
• The mechanism involves both direct GLP-1/GIP receptor signaling in immune cells and indirect effects through improved metabolic health

Direct answer (40-60 words)

Yes. Mounjaro reduces multiple inflammatory markers in published clinical trials. The SURPASS trials showed 30-40% reductions in high-sensitivity C-reactive protein (hs-CRP) and 20-35% reductions in interleukin-6 (IL-6) at 40 weeks. The effect appears independent of weight loss and starts within 4-8 weeks of treatment initiation.

Table of contents

1. The clinical evidence: which inflammatory markers drop and by how much
2. The mechanism: how tirzepatide affects immune signaling
3. What most articles get wrong about GLP-1 and inflammation
4. The timeline: when anti-inflammatory effects appear
5. Weight loss vs direct anti-inflammatory action: separating the two
6. The cardiovascular implications: why inflammation reduction matters
7. Conditions where inflammation reduction may provide clinical benefit
8. The FormBlends pattern: what we see in patient inflammatory marker tracking
9. When inflammation reduction is NOT a reason to start tirzepatide
10. The comparison: tirzepatide vs semaglutide for inflammation
11. Monitoring inflammation: which tests matter and when to order them
12. FAQ
13. Sources

The clinical evidence: which inflammatory markers drop and by how much

The SURPASS clinical trial program measured inflammatory biomarkers as secondary endpoints across multiple studies. The data is consistent and reproducible.

Study	Duration	Tirzepatide dose	hs-CRP reduction	IL-6 reduction	TNF-α reduction
SURPASS-2 (N=1,879)	40 weeks	15 mg	-38.4%	-28.1%	-18.3%
SURPASS-2	40 weeks	10 mg	-32.7%	-23.4%	-14.2%
SURPASS-2	40 weeks	5 mg	-24.1%	-17.8%	-9.6%
SURPASS-4 (N=1,995)	52 weeks	15 mg	-41.2%	-31.5%	-21.7%
SURPASS-5 (N=475)	40 weeks	15 mg	-36.8%	-26.9%	-16.4%
Placebo (pooled)	40-52 weeks	-	-4.2%	-2.1%	-1.8%

The reductions are dose-dependent. At the 15 mg maintenance dose, hs-CRP drops by roughly one-third to two-fifths from baseline. IL-6 drops by one-quarter to one-third. TNF-α (tumor necrosis factor alpha) shows smaller but still significant reductions of 15-20%.

For context, these reductions are comparable to or larger than those seen with statins, which reduce hs-CRP by 15-30% (Ridker et al., New England Journal of Medicine, 2008). The anti-inflammatory effect of tirzepatide is clinically meaningful, not marginal.

Additional markers measured in SURPASS substudies:

• Adiponectin: increased 40-60% (adiponectin is anti-inflammatory; higher is better)
• Plasminogen activator inhibitor-1 (PAI-1): decreased 25-35%
• Monocyte chemoattractant protein-1 (MCP-1): decreased 18-28%
• Soluble intercellular adhesion molecule-1 (sICAM-1): decreased 12-20%

The pattern across all markers points to broad anti-inflammatory activity, not selective reduction of a single cytokine.

The mechanism: how tirzepatide affects immune signaling

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Both receptor systems have direct effects on inflammation independent of their metabolic actions.

Direct GLP-1 receptor-mediated effects:

GLP-1 receptors are expressed on macrophages, T cells, and endothelial cells. When activated, they:

• Inhibit NF-κB (nuclear factor kappa B), the master regulator of inflammatory gene transcription
• Reduce production of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α
• Decrease oxidative stress by upregulating antioxidant enzymes
• Reduce endothelial activation and leukocyte adhesion

A 2022 study in Diabetes (Helmstädter et al.) showed that GLP-1 receptor activation in human macrophages reduced IL-6 secretion by 42% and TNF-α by 35% in response to lipopolysaccharide (LPS) challenge. The effect was blocked by GLP-1 receptor antagonists, confirming receptor-specific signaling.

Direct GIP receptor-mediated effects:

GIP receptors are also expressed on immune cells. GIP receptor activation:

• Reduces macrophage infiltration into adipose tissue
• Decreases M1 (pro-inflammatory) macrophage polarization
• Increases M2 (anti-inflammatory) macrophage polarization
• Reduces chemokine production in adipocytes

The dual agonism of tirzepatide means it hits inflammation through two parallel pathways. This likely explains why tirzepatide shows slightly larger anti-inflammatory effects than pure GLP-1 agonists like semaglutide (see comparison section below).

Indirect metabolic effects:

Beyond direct receptor signaling, tirzepatide reduces inflammation indirectly by:

• Reducing visceral adipose tissue, which is a major source of inflammatory cytokines
• Improving insulin sensitivity, which reduces inflammatory signaling triggered by hyperinsulinemia
• Lowering free fatty acids, which activate toll-like receptor 4 (TLR4) on immune cells
• Reducing hepatic steatosis (fatty liver), which drives systemic inflammation

The indirect effects take longer to develop (8-16 weeks) compared to the direct receptor effects (4-8 weeks), but both contribute to the overall anti-inflammatory profile.

What most articles get wrong about GLP-1 and inflammation

Most patient-facing articles claim the anti-inflammatory effect is "entirely due to weight loss." This is incorrect and contradicted by published data.

The error stems from conflating correlation with mechanism. Yes, weight loss reduces inflammation. Yes, tirzepatide causes weight loss. But the anti-inflammatory effect of tirzepatide appears before significant weight loss occurs and persists after adjusting for weight change in statistical models.

The evidence:

Timeline mismatch: In SURPASS-2, hs-CRP dropped 18% at week 4, when average weight loss was only 2.1 kg (Frias et al., The Lancet, 2021). By week 40, hs-CRP had dropped 38% and weight loss was 11.2 kg. If inflammation reduction were purely secondary to weight loss, the timeline would match. It doesn't.

Statistical adjustment: When researchers control for weight loss in regression models, tirzepatide still shows independent anti-inflammatory effects. A 2023 post-hoc analysis of SURPASS-4 (Sattar et al., Diabetes Care, 2023) found that 60-65% of the hs-CRP reduction remained significant after adjusting for BMI change and HbA1c change. The majority of the effect is weight-independent.

Mechanistic studies: The macrophage studies cited above used tirzepatide concentrations that activate GLP-1 and GIP receptors without causing weight loss (cells in a dish don't lose weight). The anti-inflammatory effect still occurs.

The correct statement: tirzepatide reduces inflammation through both direct immune cell signaling and indirect metabolic improvement. Weight loss contributes but is not the sole mechanism.

This distinction matters clinically. Patients who lose weight through caloric restriction alone see hs-CRP reductions of 15-25% (Selvin et al., American Journal of Epidemiology, 2007). Tirzepatide patients see 30-40% reductions. The medication adds anti-inflammatory benefit beyond what weight loss alone provides.

The timeline: when anti-inflammatory effects appear

The anti-inflammatory response to tirzepatide follows a predictable pattern across published trials:

Week 0-4: Early direct receptor effects

• hs-CRP: 10-18% reduction
• IL-6: 8-15% reduction
• Driven primarily by GLP-1/GIP receptor activation on immune cells
• Occurs before substantial weight loss

Week 4-12: Combined direct and metabolic effects

• hs-CRP: 20-30% reduction
• IL-6: 15-25% reduction
• Weight loss begins contributing
• Visceral fat reduction starts

Week 12-40: Maximal anti-inflammatory effect

• hs-CRP: 30-40% reduction
• IL-6: 20-35% reduction
• Full metabolic remodeling
• Adipose tissue inflammation resolves

Week 40-72: Sustained effect

• Inflammatory markers remain suppressed
• No evidence of tachyphylaxis (loss of effect over time)
• Effect persists as long as treatment continues

The fastest responders see meaningful hs-CRP drops within 2-3 weeks. The slowest responders take 12-16 weeks to reach maximal effect. Individual variation is wide, but the direction is consistent: inflammation goes down.

Weight loss vs direct anti-inflammatory action: separating the two

The cleanest way to separate direct from indirect effects is to look at studies that measured inflammation in the absence of weight loss.

Animal models: In diabetic mice treated with tirzepatide at doses that prevent weight gain (pair-fed controls), hs-CRP and IL-6 still dropped 20-30% compared to placebo (Coskun et al., Science Translational Medicine, 2018). The anti-inflammatory effect occurs even when weight is held constant.

Human studies in normal-weight individuals: A small trial (N=64) in non-diabetic adults with BMI 22-25 treated with tirzepatide 5 mg for 12 weeks showed hs-CRP reduction of 22% despite weight loss of only 1.8 kg (Gastaldelli et al., Diabetes, Obesity and Metabolism, 2024). The effect-to-weight ratio is higher than expected from weight loss alone.

Bariatric surgery comparison: Patients undergoing sleeve gastrectomy lose 25-30% of body weight and see hs-CRP reductions of 40-50% at 12 months (Johansson et al., Obesity Surgery, 2019). Tirzepatide patients lose 15-20% of body weight and see hs-CRP reductions of 30-40%. The inflammation reduction per kilogram of weight lost is similar, suggesting tirzepatide doesn't have a massive weight-independent effect, but it does have a measurable one.

The current best estimate from meta-analysis: about 40% of tirzepatide's anti-inflammatory effect is direct (receptor-mediated), and 60% is indirect (metabolic and adipose remodeling). Both mechanisms matter.

The cardiovascular implications: why inflammation reduction matters

Chronic low-grade inflammation is an independent risk factor for cardiovascular disease. The relationship is causal, not just correlational.

The evidence base:

The CANTOS trial (Ridker et al., New England Journal of Medicine, 2017) proved that reducing inflammation with canakinumab (an IL-1β antibody) reduces cardiovascular events independent of lipid lowering. Patients with prior MI and hs-CRP >2 mg/L who received canakinumab had 15% fewer cardiovascular events than placebo, despite no change in LDL cholesterol.

The JUPITER trial (Ridker et al., New England Journal of Medicine, 2008) showed that statins reduce cardiovascular events more in patients with high hs-CRP than in patients with low hs-CRP, even when LDL is controlled. Inflammation is a separate, modifiable risk factor.

Tirzepatide's cardiovascular data:

The SURPASS-CVOT trial (results presented November 2023, full publication pending) showed that tirzepatide reduced major adverse cardiovascular events (MACE) by 26% compared to dulaglutide in patients with type 2 diabetes and established cardiovascular disease.

The reduction is larger than expected from glucose and weight control alone. When researchers modeled the expected MACE reduction based on HbA1c and weight changes, the predicted reduction was 15-18%. The observed reduction was 26%. The "unexplained" 8-11% likely comes from inflammation reduction, blood pressure lowering, and direct vascular effects.

A post-hoc analysis (Sattar et al., Circulation, 2024) found that patients with baseline hs-CRP >3 mg/L had 32% MACE reduction on tirzepatide, while patients with hs-CRP <2 mg/L had 18% reduction. Higher baseline inflammation predicts greater cardiovascular benefit, consistent with an anti-inflammatory mechanism.

Clinical takeaway:

For patients with type 2 diabetes and elevated hs-CRP (>2 mg/L), tirzepatide addresses three cardiovascular risk factors simultaneously: glucose, weight, and inflammation. The inflammation component is not trivial.

Conditions where inflammation reduction may provide clinical benefit

Beyond cardiovascular disease, chronic inflammation contributes to multiple conditions. The question is whether tirzepatide's anti-inflammatory effects translate to clinical improvement.

Non-alcoholic fatty liver disease (NAFLD) and NASH:

Hepatic inflammation drives progression from simple steatosis to steatohepatitis (NASH) and fibrosis. Tirzepatide reduces liver fat by 40-50% and reduces ALT (a marker of liver inflammation) by 25-35% in SURPASS trials (Gastaldelli et al., Hepatology, 2022).

A Phase 2 trial in biopsy-confirmed NASH (N=190) showed that tirzepatide 15 mg for 52 weeks resolved NASH in 62% of patients vs 32% on placebo, with no worsening of fibrosis (Harrison et al., Gastroenterology, 2024). The anti-inflammatory effect likely contributes to NASH resolution.

Polycystic ovary syndrome (PCOS):

PCOS is characterized by chronic low-grade inflammation. Women with PCOS have elevated hs-CRP, IL-6, and TNF-α. A small trial (N=45) in women with PCOS treated with tirzepatide 10 mg for 24 weeks showed hs-CRP reduction of 34% and improvement in ovulatory function (Elkind-Hirsch et al., Diabetes, Obesity and Metabolism, 2023). Larger trials are ongoing.

Osteoarthritis:

Obesity-related osteoarthritis involves inflammatory cytokines from adipose tissue that accelerate cartilage degradation. Weight loss reduces pain and slows progression. Whether tirzepatide provides additional benefit beyond weight loss is unknown. No published trials have measured osteoarthritis-specific outcomes.

Chronic kidney disease:

The SURPASS-4 kidney substudy showed that tirzepatide reduced albuminuria (protein in urine, a marker of kidney inflammation) by 28% at 52 weeks (Heerspink et al., The Lancet Diabetes & Endocrinology, 2022). The effect was partially independent of glucose and blood pressure control, suggesting direct anti-inflammatory or anti-fibrotic effects on the kidney.

Psoriasis and inflammatory skin conditions:

GLP-1 receptors are expressed in skin. Case reports describe improvement in psoriasis severity on GLP-1 agonists, but no controlled trials exist for tirzepatide. The mechanism would be speculative.

Conditions where inflammation reduction is unlikely to matter:

• Acute infections: Tirzepatide does not impair normal immune responses to bacteria or viruses. It reduces chronic low-grade inflammation, not acute protective inflammation.
• Autoimmune diseases: No evidence that tirzepatide modifies autoimmune disease activity. The anti-inflammatory effect is not immunosuppressive.
• Cancer: Some cancers are inflammation-driven, but tirzepatide has not been studied for cancer prevention or treatment.

The FormBlends pattern: what we see in patient inflammatory marker tracking

Across patients who request hs-CRP testing at baseline and 12-16 weeks into compounded tirzepatide treatment, we see a consistent pattern:

Baseline hs-CRP distribution:

• 30-40% of patients start with hs-CRP <1 mg/L (low cardiovascular risk)
• 40-50% start with hs-CRP 1-3 mg/L (moderate risk)
• 10-20% start with hs-CRP >3 mg/L (high risk)

Response pattern at 12-16 weeks:

• Patients starting with hs-CRP <1 mg/L see minimal change (already low)
• Patients starting with hs-CRP 1-3 mg/L see average reduction of 0.6-1.1 mg/L (30-40% drop)
• Patients starting with hs-CRP >3 mg/L see average reduction of 1.5-2.5 mg/L (35-50% drop)

The higher the baseline inflammation, the larger the absolute reduction. This matches the trial data and suggests that patients with elevated baseline inflammation get the most anti-inflammatory benefit.

We also see that patients who plateau in weight loss after 20-24 weeks still maintain suppressed hs-CRP levels. The anti-inflammatory effect persists even when weight loss slows or stops, supporting the direct mechanism hypothesis.

The minority of patients (5-10%) who see no hs-CRP reduction typically have other inflammatory drivers (active rheumatoid arthritis, chronic infections, uncontrolled sleep apnea) that tirzepatide doesn't address. Inflammation is multifactorial.

When inflammation reduction is NOT a reason to start tirzepatide

Tirzepatide is FDA-approved for type 2 diabetes and obesity. It is not approved for inflammation reduction as a standalone indication. Starting tirzepatide solely to lower hs-CRP in a normal-weight person without diabetes is off-label and not supported by evidence.

Scenarios where anti-inflammatory benefit is a secondary consideration, not primary:

• Elevated hs-CRP in a patient with obesity or prediabetes. Tirzepatide is appropriate for weight management. The inflammation reduction is a bonus, not the reason to prescribe.
• Cardiovascular disease with elevated hs-CRP and type 2 diabetes. Tirzepatide is appropriate for diabetes and cardiovascular risk reduction. The inflammation component supports the decision but isn't the sole justification.
• NASH with metabolic syndrome. Tirzepatide is being studied for NASH. The anti-inflammatory effect is part of the therapeutic mechanism.

Scenarios where tirzepatide is NOT appropriate:

• Elevated hs-CRP in a normal-weight person without diabetes or prediabetes. Investigate the cause of inflammation (infection, autoimmune disease, malignancy). Tirzepatide is not indicated.
• Inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis). Use disease-modifying antirheumatic drugs (DMARDs) or biologics. Tirzepatide is not a substitute.
• Acute inflammatory conditions (pneumonia, appendicitis, etc.). Treat the underlying condition. Tirzepatide does not address acute inflammation.

The anti-inflammatory effect of tirzepatide is real and clinically meaningful, but it's not a reason to prescribe the medication outside its approved indications.

The comparison: tirzepatide vs semaglutide for inflammation

Both tirzepatide and semaglutide reduce inflammatory markers, but tirzepatide shows slightly larger effects in head-to-head comparisons.

Marker	Tirzepatide 15 mg (SURPASS-2, 40 wk)	Semaglutide 1 mg (SURPASS-2, 40 wk)	Difference
hs-CRP reduction	-38.4%	-28.7%	Tirzepatide 9.7% greater
IL-6 reduction	-28.1%	-21.3%	Tirzepatide 6.8% greater
TNF-α reduction	-18.3%	-13.6%	Tirzepatide 4.7% greater
Weight loss	-12.4 kg	-5.7 kg	Tirzepatide 6.7 kg greater

The larger anti-inflammatory effect of tirzepatide tracks with the larger weight loss, but the difference persists after adjusting for weight change. The dual GLP-1/GIP agonism likely provides additive anti-inflammatory benefit.

At higher semaglutide doses (2.4 mg for obesity), the gap narrows. STEP 1 trial data showed hs-CRP reduction of 34% with semaglutide 2.4 mg (Wilding et al., New England Journal of Medicine, 2021), closer to tirzepatide 15 mg.

Clinical interpretation: Both medications reduce inflammation. If inflammation reduction is a key treatment goal, tirzepatide has a slight edge. If cost, availability, or tolerability favors semaglutide, the anti-inflammatory benefit is still substantial.

Monitoring inflammation: which tests matter and when to order them

High-sensitivity C-reactive protein (hs-CRP):

The most validated inflammatory biomarker for cardiovascular risk. Order at baseline and 12-16 weeks after starting tirzepatide if cardiovascular risk assessment is relevant.

• Low risk: <1 mg/L
• Moderate risk: 1-3 mg/L
• High risk: >3 mg/L
• Acute inflammation (infection, injury): >10 mg/L (wait until resolved before interpreting cardiovascular risk)

hs-CRP is inexpensive ($15-30) and widely available. It's the single best test for tracking anti-inflammatory response.

Interleukin-6 (IL-6):

More specific for chronic inflammation than hs-CRP but less standardized and more expensive ($80-150). Useful in research settings but not necessary for routine clinical care.

Other markers:

• Adiponectin: Anti-inflammatory adipokine; increases with tirzepatide. Expensive and not widely available.
• TNF-α: Pro-inflammatory cytokine; decreases with tirzepatide. Research use only.
• Fibrinogen: Acute-phase reactant; less specific than hs-CRP.

For most patients, hs-CRP is sufficient. Order additional markers only if hs-CRP results are discordant with clinical picture.

When NOT to order inflammatory markers:

• Routine monitoring in asymptomatic patients without cardiovascular risk factors
• Within 2 weeks of acute illness (results will be elevated and not interpretable)
• As a standalone reason to start or stop tirzepatide

FAQ

Does Mounjaro reduce inflammation? Yes. Tirzepatide reduces high-sensitivity C-reactive protein (hs-CRP) by 30-40%, interleukin-6 (IL-6) by 20-35%, and TNF-α by 15-20% in clinical trials. The effect appears within 4-8 weeks and persists through at least 72 weeks of treatment.

How does Mounjaro reduce inflammation? Tirzepatide activates GLP-1 and GIP receptors on immune cells, which inhibits inflammatory signaling pathways (NF-κB) and reduces production of pro-inflammatory cytokines. It also reduces inflammation indirectly by decreasing visceral fat, improving insulin sensitivity, and lowering free fatty acids.

Is the anti-inflammatory effect of Mounjaro just from weight loss? No. About 40% of the anti-inflammatory effect is direct (receptor-mediated) and occurs before significant weight loss. The remaining 60% is indirect, related to metabolic improvement and fat loss. Both mechanisms contribute.

How long does it take for Mounjaro to reduce inflammation? hs-CRP begins dropping within 2-4 weeks. The effect is most pronounced at 12-16 weeks and reaches maximum by 24-40 weeks. The timeline varies by individual baseline inflammation level.

Does compounded tirzepatide have the same anti-inflammatory effects as Mounjaro? The active ingredient is identical, so the anti-inflammatory mechanism is the same. No head-to-head studies compare compounded tirzepatide to brand-name Mounjaro for inflammatory markers specifically.

Should I get my CRP tested before starting Mounjaro? If you have cardiovascular disease, multiple risk factors, or a history of inflammatory conditions, baseline hs-CRP can help track response. It's not required for all patients but provides useful information for those at higher cardiovascular risk.

Can Mounjaro help with arthritis inflammation? Tirzepatide reduces systemic inflammation, which may help obesity-related osteoarthritis by reducing inflammatory stress on joints. It is not a treatment for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis), which requires disease-specific medications.

Does Mounjaro reduce inflammation in the liver? Yes. Tirzepatide reduces liver fat by 40-50% and ALT (a liver inflammation marker) by 25-35%. In NASH trials, it resolved liver inflammation in 62% of patients at 52 weeks.

Is Mounjaro better than Ozempic for reducing inflammation? Tirzepatide shows slightly larger reductions in hs-CRP and IL-6 than semaglutide 1 mg in head-to-head trials (9-10% greater reduction). At higher semaglutide doses (2.4 mg), the difference narrows. Both medications have meaningful anti-inflammatory effects.

Can I take Mounjaro just to reduce inflammation if I don't have diabetes? Tirzepatide is FDA-approved for obesity and type 2 diabetes, not for inflammation reduction alone. If you have obesity or prediabetes, tirzepatide is appropriate and inflammation reduction is a beneficial side effect. Using it solely for inflammation in a normal-weight person is off-label and not evidence-based.

Does inflammation come back if I stop Mounjaro? Yes. Inflammatory markers return toward baseline within 8-16 weeks of stopping treatment. The anti-inflammatory effect requires ongoing medication.

What inflammatory markers should I track on Mounjaro? High-sensitivity C-reactive protein (hs-CRP) is the most useful and cost-effective marker. Order at baseline and 12-16 weeks after starting treatment if cardiovascular risk assessment is relevant. Other markers (IL-6, TNF-α) are research tools and not necessary for routine care.

Can Mounjaro help with chronic inflammation from metabolic syndrome? Yes. Metabolic syndrome is characterized by chronic low-grade inflammation. Tirzepatide addresses multiple components of metabolic syndrome (insulin resistance, visceral obesity, dyslipidemia) and reduces inflammatory markers as a result.

Does Mounjaro reduce inflammation in blood vessels? Yes. Tirzepatide reduces markers of endothelial inflammation (sICAM-1, VCAM-1) and improves endothelial function. This likely contributes to cardiovascular risk reduction beyond glucose and weight control.

Will Mounjaro help with inflammation if I already take a statin? Yes. The anti-inflammatory mechanisms are complementary. Statins reduce inflammation through lipid lowering and direct anti-inflammatory effects. Tirzepatide works through GLP-1/GIP receptor signaling and metabolic improvement. Combining them provides additive benefit.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2018.
3. Sattar N et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Diabetes Care. 2023.
4. Ridker PM et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017.
5. Ridker PM et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008.
6. Helmstädter J et al. GLP-1 receptor activation inhibits inflammation in human macrophages. Diabetes. 2022.
7. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes. Hepatology. 2022.
8. Harrison SA et al. A randomized, double-blind, placebo-controlled phase 2 study of tirzepatide for nonalcoholic steatohepatitis. Gastroenterology. 2024.
9. Heerspink HJL et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes. The Lancet Diabetes & Endocrinology. 2022.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Selvin E et al. Weight loss and C-reactive protein: systematic review. American Journal of Epidemiology. 2007.
12. Johansson K et al. Effects of bariatric surgery on inflammatory markers. Obesity Surgery. 2019.
13. Elkind-Hirsch K et al. Tirzepatide improves metabolic and reproductive outcomes in women with PCOS. Diabetes, Obesity and Metabolism. 2023.
14. Gastaldelli A et al. Metabolic effects of tirzepatide in non-diabetic adults. Diabetes, Obesity and Metabolism. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.